Join
Live feed
·
PRReleasevia Quantisnow
Harmony Biosciences Holdings Inc. logo

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

ByQuantisnow·Wall Street's wire, on your screen.
HRMY· Harmony Biosciences Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HRMY (Harmony Biosciences Holdings Inc.) and more on Quantisnow.

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs | Quantisnow